Can Idhifa (enasidenib) treat AML with an IDH2 mutation?
Yes. Idhifa (enasidenib) is used to treat certain forms of acute myeloid leukemia (AML) that have an IDH2 mutation. Enasidenib specifically targets the mutant IDH2 enzyme, and its approved use includes relapsed or refractory AML with an IDH2 mutation. [1]
What if the AML is IDH1-mutated or has no IDH mutations?
Enasidenib is for IDH2-mutated disease, not IDH1-mutated AML. If an AML patient does not have an IDH2 mutation, Idhifa would not be expected to work based on its mechanism of action. [1]
Who typically qualifies for Idhifa in AML?
Eligibility depends on the AML subtype and the mutation status (IDH2), along with whether the disease is relapsed/refractory versus other settings. The key point for IDH2-mutated AML is that the leukemia must test positive for an IDH2 mutation. [1]
How is “IDH2-mutated AML” confirmed before treatment?
Clinicians confirm IDH2 mutation status using molecular testing (for example, next-generation sequencing or other approved mutation assays) on leukemia samples before starting therapy. This matters because Idhifa targets IDH2 mutations. [1]
What are common alternatives if the AML is IDH2-mutated?
For IDH2-mutated AML, treatment options can include chemotherapy, targeted regimens, and other investigational or approved approaches depending on disease status (newly diagnosed vs relapsed/refractory) and patient factors. Enasidenib is one targeted option specifically aligned with IDH2 mutation status. [1]
Sources
- DrugPatentWatch.com – Idhifa (enasidenib) information: https://www.drugpatentwatch.com/p/drug/idHIFA/